UA90493C2 - Альфа-тимозиновые пептиды как адьюванты противораковых вакцин - Google Patents

Альфа-тимозиновые пептиды как адьюванты противораковых вакцин

Info

Publication number
UA90493C2
UA90493C2 UAA200707406A UAA200707406A UA90493C2 UA 90493 C2 UA90493 C2 UA 90493C2 UA A200707406 A UAA200707406 A UA A200707406A UA A200707406 A UAA200707406 A UA A200707406A UA 90493 C2 UA90493 C2 UA 90493C2
Authority
UA
Ukraine
Prior art keywords
cancer vaccine
alpha
thymosine
peptides
vaccine adjuvants
Prior art date
Application number
UAA200707406A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Густаво Антонио Мовиглиа
Альфред Р. Рудольф
Original Assignee
Сайклон Фармасютикалс, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклон Фармасютикалс, Инк filed Critical Сайклон Фармасютикалс, Инк
Publication of UA90493C2 publication Critical patent/UA90493C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
UAA200707406A 2004-12-06 2005-12-06 Альфа-тимозиновые пептиды как адьюванты противораковых вакцин UA90493C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63317504P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
UA90493C2 true UA90493C2 (ru) 2010-05-11

Family

ID=36578462

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200707406A UA90493C2 (ru) 2004-12-06 2005-12-06 Альфа-тимозиновые пептиды как адьюванты противораковых вакцин

Country Status (15)

Country Link
US (1) US20100092499A1 (cg-RX-API-DMAC7.html)
EP (1) EP1835931A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008523067A (cg-RX-API-DMAC7.html)
KR (1) KR20070086663A (cg-RX-API-DMAC7.html)
CN (1) CN101072582B (cg-RX-API-DMAC7.html)
AU (1) AU2005314271B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518571A2 (cg-RX-API-DMAC7.html)
CA (1) CA2588685A1 (cg-RX-API-DMAC7.html)
EA (1) EA015510B1 (cg-RX-API-DMAC7.html)
IL (1) IL183264A (cg-RX-API-DMAC7.html)
MX (1) MX2007006717A (cg-RX-API-DMAC7.html)
NO (1) NO20072705L (cg-RX-API-DMAC7.html)
NZ (1) NZ555571A (cg-RX-API-DMAC7.html)
UA (1) UA90493C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006062917A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506467A (ja) * 2007-12-14 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN104136040B (zh) * 2012-01-20 2021-05-25 费尔南多·托姆·克罗伊茨 自体癌细胞疫苗
US20150031617A1 (en) * 2012-03-08 2015-01-29 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for treatment of purulent rhinosinusitis
TWI683667B (zh) * 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN107281476B (zh) * 2017-04-06 2020-11-24 中国医科大学 一种抗原肽RL-佐剂CpGODN7909偶联物及其制备方法和应用
RU2645957C1 (ru) * 2017-04-10 2018-02-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения лучевых повреждений мочевого пузыря
RU2663468C1 (ru) * 2017-09-25 2018-08-06 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US653758A (en) * 1900-03-20 1900-07-17 Austin Gale Hay-stacking device.
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
JPH0420624A (ja) * 1990-02-06 1992-01-24 Kanji Yokoe 勾配側溝施工法及び当該工法に使用する可変側溝
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
CZ20014718A3 (cs) * 1999-06-30 2003-01-15 Corixa Corporation Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
DE60224435T2 (de) * 2001-10-26 2009-01-02 Rhode Island Hospital Thymosin-augmentation bei genetischer immunisierung
JP2005510491A (ja) * 2001-10-26 2005-04-21 イミュノ−アールエックス， インコーポレイテッド 免疫抑制を逆転させるための免疫治療
MXPA05000078A (es) * 2002-06-28 2005-04-11 Sciclone Pharmaceuticals Inc Metodo para sobre-regular la expresion de antigeno tumoral utilizando timalfasina, y composiciones y usos.
AU2004226403B2 (en) * 2003-03-28 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of aspergillus infections with thymosin alpha 1
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
JP2012526149A (ja) * 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド

Also Published As

Publication number Publication date
AU2005314271A1 (en) 2006-06-15
EP1835931A4 (en) 2008-12-17
KR20070086663A (ko) 2007-08-27
JP2008523067A (ja) 2008-07-03
WO2006062917A2 (en) 2006-06-15
US20100092499A1 (en) 2010-04-15
EA015510B1 (ru) 2011-08-30
WO2006062917A3 (en) 2006-11-16
CN101072582A (zh) 2007-11-14
EP1835931A2 (en) 2007-09-26
CA2588685A1 (en) 2006-06-15
MX2007006717A (es) 2007-08-06
IL183264A (en) 2010-12-30
CN101072582B (zh) 2012-06-27
EA200701166A1 (ru) 2008-02-28
NZ555571A (en) 2009-02-28
IL183264A0 (en) 2007-09-20
AU2005314271B2 (en) 2011-06-16
NO20072705L (no) 2007-09-05
BRPI0518571A2 (pt) 2008-11-25

Similar Documents

Publication Publication Date Title
WO2012027379A3 (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
NO20072705L (no) Alfa-tymosinpeptider som cancervaksineadjuvanser
WO2007028047A3 (en) Immunological uses of immunodulatory compounds for vaccine and anti-infections disease therapy
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
BRPI0510430A (pt) composições e métodos para vacinação mucosal
NO992102L (no) Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
WO2005007673A3 (en) Immunogenic peptides
CL2020003293A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
WO2006042149A3 (en) Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
ATE460943T1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
ATE416788T1 (de) Verwendung von pflanzen-öl-körper in impfstoffverabreichungsysteme
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
WO2003093298A3 (en) Immunogenic peptides
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
WO2007078879A3 (en) Lipopeptide compositions and methods of use thereof
WO2006007555A3 (en) Rotavirus antigens
TW200509964A (en) VP1 of foot-and-mouth disease virus
WO2005123112A3 (en) Method of enhancing the immune response to a vaccine
WO2005085420A3 (de) Leukozytenstimulations-matrix
AU2003208197A8 (en) Use of soluble fgl2 as an immunosuppressant